Inhibitors Of P53-mdm2 Interaction

Abstract

The present invention describes the compound of general formula 1 (Formula 1) their salts or esters for the treatment of diseases that are positively influenced by the inhibition of p53-MDM2 or p53-MDMX interaction. In particular for the treatment of neoplasias, preferably for the treatment of cancer, namely breast, colorectal, prostate, kidney, lung cancers, melanoma, osteosarcoma or embryonal nephroma, among others.


Claims
Download PDF
Document Preview
Document History
  • Publication: Jul 18, 2013
  • Application: Jan 9, 2013
    WO IB 2013050193 W
  • Priority: Jan 9, 2012
    PT PT 10608812 A

Download Citation


Sign in to the Lens

Feedback